Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 4/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5993914 | 0.84 | SLC6A2 (0.59) | SLC6A2SLC6A4GPR119MEN1KMT2A | |
| SCHEMBL5996568 | 0.82 | SLC6A2 (0.55) | SLC6A2SLC6A4GPR119MEN1KMT2A | |
| SCHEMBL5996937 | 0.82 | SLC6A2 (0.57) | SLC6A2SLC6A4GPR119MEN1KMT2A | |
| SCHEMBL5993248 | 0.82 | MEN1 (0.47) | SLC6A2SLC6A4GPR119MEN1KMT2A | |
| SCHEMBL5995606 | 0.82 | SLC6A2 (0.51) | SLC6A2SLC6A4GPR119MEN1KMT2A | |
| Acetic Acid SCHEMBL5993263 | 0.82 | SLC6A2 (0.58) | SLC6A2SLC6A4GPR119MEN1KMT2A | |
| SCHEMBL5994302 | 0.81 | SLC6A2 (0.56) | SLC6A2SLC6A4GPR119MEN1KMT2A | |
| SCHEMBL5996956 | 0.80 | SLC6A2 (0.58) | SLC6A2SLC6A4GPR119MEN1KMT2A | |
| SCHEMBL1815968 | 0.79 | KDM4E (0.54) | GPR119MEN1KMT2AEPHX2CYP2C9 | |
| SCHEMBL4690064 | 0.77 | SLC6A2 (0.53) | SLC6A2SLC6A4GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | ELI LILLY AND COMPANY | 2006-04-13 | — | — | US | disclosed |
| EP-1569905-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2004052858-A2 | INHIBITORS OF MONOAMINE UPTAKE | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079554-A1 | Inhibitors of monomine uptake | SLC6A2, SLC18A2, SLC6A3 | SLC6A2 1/4885SLC6A4 4/4885GPR119 178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.